Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive and rapid metastasis with median survival of less than 6 months. Multimodal treatment involving surgery and chemoradiotherapy has been used to improve the survival of patients. Here, we retrospectively review of treatment outcome of 13 consecutive patients who were treated at a single center. Materials and Methods: We retrospectively reviewed medical records of 13 anaplastic thyroid cancer patients who received multidisciplinary treatment between 2006 and 2010. Kaplan-Meier survival curve was used to analyze progression-free survival and overall survival of patients. Results: The median patient age at diagnosis was 69 years, and six patients had stage IVc diseases. Eight patients received primary surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five patients received weekly doxorubicin-based definitive CCRT, but only one patient’s condition remained stable, while the rest experienced rapid disease progression. The median progression-free survival was 2.8 months (95% CI, 1.2-4.4 months), and the median overall survival was 3.8 months (95% CI, 3.0-4.6 months). Conclusion: Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment. Therefore, identification of novel therapeutic targets is warranted to take an effective mode of treatment.
Abstract
Purpose: Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive and rapid metastasis with median survival of less than 6 months. Multimodal treatment involving surgery and chemoradiotherapy has been used to improve the survival of patients. Here, we retrospectively review of treatment outcome of 13 consecutive patients who were treated at a single center. Materials and Methods: We retrospectively reviewed medical records of 13 anaplastic thyroid cancer patients who received multidisciplinary treatment between 2006 and 2010. Kaplan-Meier survival curve was used to analyze progression-free survival and overall survival of patients. Results: The median patient age at diagnosis was 69 years, and six patients had stage IVc diseases. Eight patients received primary surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five patients received weekly doxorubicin-based definitive CCRT, but only one patient’s condition remained stable, while the rest experienced rapid disease progression. The median progression-free survival was 2.8 months (95% CI, 1.2-4.4 months), and the median overall survival was 3.8 months (95% CI, 3.0-4.6 months). Conclusion: Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment. Therefore, identification of novel therapeutic targets is warranted to take an effective mode of treatment.
참고문헌 (22)
- Kebebew E, "Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors", Cancer, 103, pp.1330~1335 (2005)
- Gilliland FD, "Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991", Cancer, 79, pp.564~573 (1991)
- McIver B, "Anaplastic thyroid carcinoma: a 50-year experience at a single institution", Surgery, 130, pp.1028~1034 (2001)
- Pierie JP, "The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma", Ann Surg Oncol, 9, pp.57~64 (2002)
- Kim JH, "Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach", Cancer, 52, pp.954~957 (1983)
- Kim JH, "Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy", Cancer, 60, pp.2372~2375 (1987)
- De Besi P, "Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer", J Endocrinol Invest, 14, pp.475~480 (1991)
- Ain KB., "Management of undifferentiated thyroid cancer", Baillieres Best Pract Res Clin Endocrinol Metab, 14, pp.615~629 (2000)
- Chen J, "Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002", Am J Clin Oncol, 31, pp.460~464 (2008)
- Wang Y, "Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens", Cancer, 107, pp.1786~1792 (2006)
- Union Internationale Contre le Cancer, "TNM classification of malignant tumors. 6th ed" (2002), Wiley-Liss
- 장항석, "Anaplastic Thyroid Carcinoma: A Therapeutic Dilemma", Yonsei Medical Journal, 46(6), pp.759~764 (2005), 연세대학교의과대학
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Swaak-Kragten AT, "Multimodality treatment for anaplastic thyroid carcinoma-- treatment outcome in 75 patients", Radiother Oncol, 92, pp.100~104 (2009)
- Tennvall J, "Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery", Br J Cancer, 86, pp.1848~1853 (2002)
- De Crevoisier R, "Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy", Int J Radiat Oncol Biol Phys, 60, pp.1137~1143 (2004)
- Troch M, "High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel", J Clin Endocrinol Metab, 95, pp.54~57 (2010)
- Wiseman SM, "Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment", Ann Surg Oncol, 14, pp.719~729 (2007)
- Baselga J, "Critical update and emerging trends in epidermal growth factor receptor targeting in cancer", J Clin Oncol, 23, pp.2445~2459 (2005)
- Kim S, "Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice", Clin Cancer Res, 12, pp.600~607 (2006)
- Antonelli A, "Dedifferentiated thyroid cancer: a therapeutic challenge", Biomed Pharmacother, 62, pp.559~563 (2008)
- Antonelli A, "Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests", Clin Endocrinol (Oxf), 69, pp.148~152 (2008)